Evaluation of the Efficacy of the Compound Actinomycin D in Tumor Cell Lines

  • R. Cibi
  • Published 2016

Abstract

Actinomycin D is the best known compound from the actinomycin group whose wide application potential has been extensively studied. Actinomycin D is a orange red compound having two cyclic pentapeptide lactones attached to 2 amino-4,6-dimethyl3-oxo-phenoxazine -1,9-dicarboxylic acid, first reported in Streptomyces antibioticus (Waksman and Woodruff, 1940). Subsequently number of other bacteria were also reported to produce actinomycin D including Streptomyces fradiae (Bossi et al., 1958), Streptomyces parvulus (Williams and Katz, 1977), Streptomyces plicatus (Lam et al., 2002), Streptomyces violascens (Roos and Loane, 2004), Streptomyces sindenensis (Praveen et al., 2008) etc. Actinomycin D is found to be the most effective natural analog for the treatment of cancer in children and adults. It has been used clinically as a chemotherapeutic agent for the treatment of Wilm’s tumor with 90% cure rate (Green, 1997; Farber et al., 2002) and rhabdomyosarcoma (Womer, 1997). This compound was approved for the treatment of pediatric solid tumors by US FDA in 1964(Newman and Cragg, 2007). The biological activity is due to the abilityof actinomycin D to intercalate with the DNA double helix and there by inhibiting DNA directed RNA synthesis, this prevents unwinding of the DNA to facilitate its International Journal of Current Microbiology and Applied Sciences ISSN: 2319-7706 Volume 5 Number 7 (2016) pp. 405-411 Journal homepage: http://www.ijcmas.com

2 Figures and Tables

Cite this paper

@inproceedings{Cibi2016EvaluationOT, title={Evaluation of the Efficacy of the Compound Actinomycin D in Tumor Cell Lines}, author={R. Cibi}, year={2016} }